European Medicines Agency clarifies rules on fees
The European Medicines Agency has revised the rules on fees payable to the Agency. The revised rules, which came into force on 24 August 2012, now include clarification on:
- the definitions of type-II quality variations, which now include references to non-clinical data for basic fees;
- the mechanism for financial compensation for national competent authorities and inspectorates.
Further details are available in the explanatory note on fees payable to the Agency.
How useful is this page?
Average rating:Based on 2 ratings
Add your rating:
- See all ratings
1 ratings0 ratings0 ratings0 ratings1 ratings